RBC Capital analyst Conor McNamara reiterated a Buy rating on SOPHiA GENETICS (SOPH – Research Report) yesterday and set a price target of $8.00. The company’s shares closed yesterday at $4.97.
According to TipRanks, McNamara is an analyst with an average return of -9.5% and a 36.08% success rate. McNamara covers the Healthcare sector, focusing on stocks such as QuidelOrtho, Bio-Rad Laboratories, and Maravai Lifesciences Holdings.
SOPHiA GENETICS has an analyst consensus of Strong Buy, with a price target consensus of $8.00.
The company has a one-year high of $7.37 and a one-year low of $2.13. Currently, SOPHiA GENETICS has an average volume of 66.61K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SOPHiA GENETICS (SOPH) Company Description:
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.
Read More on SOPH:
- Sophia Genetics Q1 Loss Narrows, Revenue Up
- Sophia Genetics management to meet with BTIG
- SOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Healthcare Conference
- SOPHiA GENETICS to Announce Financial Results for First Quarter 2024 on May 7, 2024
- Sophia Genetics reports Syndicate Bio as first liquid biopsy customer in Africa
